Multiple Sclerosis clinical trial pipeline is active with 60+ key companies, driving market growth
From GlobeNewswire: 2025-06-24 13:00:00
Multiple Sclerosis Clinical Trial Pipeline Shows Potential with Active Contributions from 60+ Key Companies. Rising prevalence of MS is driving significant investment in research and development for effective treatments, compelling healthcare stakeholders to allocate resources and develop strategies, fueling market growth.
DelveInsight’s ‘Multiple Sclerosis Competitive Landscape 2025’ report provides comprehensive global coverage of pipeline MS medication in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the MS pipeline domain.
Key takeaways from the report depict a robust space with 60+ active players working to develop 75+ pipeline MS treatments. Key companies like Sanofi, Immunic, InnoCare Pharma, and others are evaluating promising pipeline drugs under different phases of clinical trials.
MS is the most common neurological condition affecting young adults, typically starting between ages 20-40. It targets axons in the CNS protected by myelin, with the relapsing-remitting form being the most common. Symptoms include visual disturbances, muscle weakness, numbness, and pain.
Around 400,000 people in the U.S. and 2.5 million globally are affected by MS, with a higher prevalence in women. The core cause of MS-related damage is inflammation within the CNS, with genetic, environmental, and infectious factors playing a role in its development.
Diagnosis of MS involves a combination of clinical history, physical and neurological exams, MRI imaging, evoked potential tests, and cerebrospinal fluid analysis. Treatment includes disease-modifying therapies and symptomatic treatments, with 12 treatments approved by the EMA and FDA.
The MS market is driven by scientific innovation, an expanding patient population, and a robust pipeline of DMTs. Intense competition among established drugs and market access challenges are shaping the market dynamics, with a focus on real-world evidence and value-based care.
Pipeline development of novel therapies targeting mechanisms like BTK inhibitors, remyelination agents, and cell-based therapies is influencing the MS market dynamics. Market access and pricing pressures are driving companies to demonstrate value and navigate complex reimbursement frameworks.
The MS market is highly dynamic and competitive, with rapid innovation and evolving stakeholder expectations. Future growth depends on therapeutic advancements, addressing unmet needs, and adapting to changing policy environments for a transformed treatment landscape.
Read more at GlobeNewswire: Multiple Sclerosis Clinical Trial Pipeline Shows Potential